Alessandro D. Santin MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., University of Brescia School of Medicine (1989)
  • Resident, University of Brescia School of Medicine , Obstetrics & Gynecology (1990 - 1993)
  • Fellow, University of Arkansas for Medical Sciences , Gynecology Oncology (1995 - 2000)
  • Fellow, University of California - Irvine Medical Center , Gynecology Oncology (1993 - 1995)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Cancer of the ovary, uterus, vagina, cervix and vulva; Intraperitoneal chemotherapy; Tumor immunology and immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in Gynecologic Oncology


Cancers Treated

Cervix, Gestational Trophoblastic Neoplasia, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Obstetrics & Gynecology, FB (1993)

Clinical Trials

ConditionsStudy Title
Endometrial Cancer and Corpus UteriA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Other Female Genital, and OvaryChemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG 0273)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.

Edit Profile